Comar
Comar is reportedly leading the way in developing SecureCap child-resistant (CR) closures in response to the Consumer Product Safety Commission (CPSC) rule requiring CR packaging for products containing the equivalent of 0.08 mg or more of imidazoline.
The SecureCap CR closures utilise Comar’s existing two-piece push and turn technology with proven CR and SF (senior friendly) effectiveness.
The technology is a natural progression for Comar and comprised of a two-component system (inner and outer) originally designed and utilised in the market for the company’s dropper assemblies. The CR dropper caps are currently standard stocked items in 20, 24 and 28 mm sizes.
CPSC mini protocol tests were completed with positive results in mid-May 2013, with a full protocol to follow and commercialisation expected later this year.
Sizes ranging from 13 to 15 mm for ophthalmic and 15 to 18 mm for nasal will be offered and various sample sizes are now available.
SecureCap CR closures are patent pending and will be CE marked. System components are manufactured in facilities that comply with cGMP and ISO 9001:13485 quality standards. Comar provides manufacturing services for pharmaceutical and Class 1 medical device moulding.
Comar, Inc., +1 856 507 5402, evansl@comar.com, www.comar.com.